Skip to main
KIDS

OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics (KIDS) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

OrthoPediatrics Corp demonstrated a solid financial performance characterized by an increase in gross margin by 50 basis points year-over-year and an impressive rise in adjusted EBITDA margin by 280 basis points. The company's Trauma & Deformity sales grew by 17.3% to $44.1 million, outperforming estimates, and management highlighted a significant growth rate of over 20% in the OPSB category for the third quarter of 2025. Looking ahead, the company anticipates continued revenue growth of over 12% in the coming years, with expectations for improved margins driven by new product introductions and enhanced operating leverage.

Bears say

The analysis of OrthoPediatrics Corp reveals several fundamental concerns that contribute to a negative outlook on the stock. Key financial metrics indicate a slowdown in revenue growth, with the KIDS segment experiencing a decline from 15.7% in Q2 2025 to 12.2% in Q3 2025, raising fears of further stagnation amidst challenges related to sales rep attrition and new product launches. Additionally, declining productivity gains among distributors and a drop in deployed sets from $5.3 million in Q3 2024 to $4.1 million in Q3 2025 suggest potential weaknesses in revenue generation and margin improvement, prompting a downward revision of FY25 guidance to between $233.5 million and $234.5 million.

OrthoPediatrics (KIDS) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OrthoPediatrics (KIDS) Forecast

Analysts have given OrthoPediatrics (KIDS) a Strong Buy based on their latest research and market trends.

According to 9 analysts, OrthoPediatrics (KIDS) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OrthoPediatrics (KIDS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.